## UNITED STATES DISTRICT COURT WESTERN DISTRICT OF LOUISIANA LAKE CHARLES DIVISION

RHONDA BREAUX, : CASE NO. 2:23-cv-1365

:

Plaintiff, : JUDGE JAMES D. CAIN, JR.

:

**v.** 

: MAGISTRATE JUDGE KATHLEEN KAY

NOVO NORDISK A/S, NOVO NORDISK:
NORTH AMERICA OPERATIONS A/S,:
NOVO NORDISK US HOLDINGS INC.,:
NOVO NORDISK US COMMERCIAL:
HOLDINGS INC., NOVO NORDISK:
INC., NOVO NORDISK RESEARCH:
CENTER SEATTLE INC. AND NOVO:

CENTER SEATTLE, INC., AND NOVO : NORDISK PHARMACEUTICAL :

INDUSTRIES, LP

:

Defendants.

## NOVO NORDISK DEFENDANTS' CONSENT MOTION FOR EXTENSION OF TIME

Defendants, Novo Nordisk US Holdings Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk Inc., Novo Nordisk Research Center Seattle, Inc., and Novo Nordisk Pharmaceutical Industries, LP ("Novo Nordisk Defendants"), respectfully request an extension of time until November 14, 2023 (from the date the response would otherwise be due – October 24, 2023), to file an answer or other responsive pleadings in this matter.

In accordance with Uniform District Court Rules, Local Rule 7.9, counsel for Novo Nordisk Defendants certify that they have sought and obtained Plaintiff's consent to this motion.

<sup>&</sup>lt;sup>1</sup> As of October 9, 2023, Plaintiff has not served Novo Nordisk A/S or Novo Nordisk North America Operations A/S.

**WHEREFORE**, Novo Nordisk Defendants pray that their motion be granted, and that they be granted until November 14, 2023, within which to file an answer or otherwise responsive pleadings.

Respectfully submitted,

## ADAMS AND REESE LLP

/s/ Diana Cole Surprenant

E. Paige Sensenbrenner (LA Bar No. 18429) Diana Cole Surprenant (LA Bar No. 33399) 701 Poydras Street Suite 4500 New Orleans, LA 70139

Tel: (504) 581-3234

Email: paige.sensenbrenner@arlaw.com Email: diana.surprenant@arlaw.com

**AND** 

## **DLA PIPER LLP (US)**

/s/ Loren H. Brown

Loren H. Brown (*pro hac vice forthcoming*) 1251 Avenue of the Americas 27th Floor New York, NY 10020-1104

Tel: (212) 335-4846

Email: loren.brown@us.dlapiper.com

Attorneys for Defendants Novo Nordisk US Holdings Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk Inc., Novo Nordisk Research Center Seattle, Inc., and Novo Nordisk Pharmaceutical Industries, LP